ArticleReviews in urology2008
Clinical utility of prostate carcinoma molecular diagnostic tests.
Article in Reviews in urology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Review
- Long non-coding RNAeLife · 2024Article
- Diagnostic utility of a-methylacyl COA racemase in prostate cancer of the Iranian population.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2021Article
- NONHSAT076754 aids ultrasonography in predicting lymph node metastasis and promotes migration and invasion of papillary thyroid cancer cells.Oncotarget · 2017Article
- Long Noncoding RNAs as Biomarkers in Cancer.Disease markers · 2017Review
- Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.Molecular medicine reports · 2016Article
- Long non-coding RNAs in cancer: implications for personalized therapy.Cellular oncology (Dordrecht, Netherlands) · 2015Review
- Serum LncRNAs Profiles Serve as Novel Potential Biomarkers for the Diagnosis of HBV-Positive Hepatocellular Carcinoma.PloS one · 2015Article
- Review
- Non-Coding RNAs: Functional Aspects and Diagnostic Utility in Oncology.International journal of molecular sciences · 2013Article
- Prostate-specific antigen: any successor in sight?Reviews in urology · 2013Review
- Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM).PloS one · 2013Article
- Biopsy and treatment decisions in the initial management of prostate cancer and the role of PCA3; a systematic analysis of expert opinion.World journal of urology · 2012Article
- Perspectives of Long Non-Coding RNAs in Cancer Diagnostics.Frontiers in genetics · 2012Article
- Urine markers and prostate cancer.Central European journal of urology · 2011Review
- Prostate Cancer Specificity of PCA3 Gene Testing: Examples from Clinical Practice.Reviews in urology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Instead of relying on serum prostate-specific antigen (PSA) to identify patients for prostate biopsy, new laboratory tests are needed that have improved specificity for prostate carcinoma (CaP), allow accurate classification of clinically insignificant CaPs, allow for detection of clinically significant CaP in patients without elevated serum PSA, and allow for identification of aggressive forms of CaP, which may warrant adjunctive or even molecularly targeted therapy in the future. Over the last several years, high-throughput gene expression profiling and proteinomics have led to the identification of genes and proteins that are specifically overexpressed in CaP. Molecular diagnostic techniques readily translated to the clinical laboratory have been incorporated into the development of new tests based on these novel molecular alterations in CaP. Some of these tests already have well-documented clinical utility, such as in facilitating prostate biopsy decisions, and are routinely available. The current review focuses on the biological, clinical, and laboratory aspects of the most promising of these current and near-future molecular CaP tests.
Indexed as
Identifiers
18470278PMC2312347W1579882000What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.